Reverse DCF
What growth rate is priced into UroGen Pharma Ltd (URGN)?
At the current market price of $46.96, a reverse DCF implies UroGen Pharma Ltd (URGN) must grow revenue about 39.4% per year for the next decade (74.0% in year one) to be worth what it trades for — holding margins, taxes, reinvestment, and the discount rate fixed at the model's baseline assumptions.
Market price
$46.96
Implied growth (yr 1)
74.0%
Implied 10-yr CAGR
39.4%
UroGen Pharma Ltd (URGN) reverse DCF FAQ
What revenue growth rate is priced into UroGen Pharma Ltd (URGN)?
At the current market price of $46.96, a reverse DCF implies UroGen Pharma Ltd's revenue must grow about 39.4% per year for the next ten years (starting at 74.0% in year one) to justify the price — holding margins, taxes, reinvestment, and the discount rate at the model's baseline assumptions.
What is a reverse DCF?
A regular DCF turns growth assumptions into a fair value. A reverse DCF inverts that: it holds every other assumption fixed and solves for the single revenue-growth path that makes intrinsic value equal the current market price. The result is the growth the market is already paying for — a hurdle you can judge the business against.
How does the implied growth compare with the model's own URGN forecast?
The forward DCF for UroGen Pharma Ltd estimates a fair value of $0.38 per share, implying URGN is overvalued at the $46.96 market price. If the market-implied growth is well above what the forward model assumes, the price embeds more optimism than the fundamentals-anchored forecast — and vice versa.
How this URGN implied growth is solved
The engine takes the same 10-year DCF used for the UroGen Pharma Ltd fair-value estimate — margins converging to Damodaran industry benchmarks, year-by-year WACC, a reinvestment rate tied to sales-to-capital efficiency — and inverts it: instead of projecting growth to get a value, it bisects on the starting revenue-growth rate, re-running the valuation until intrinsic value matches the market price. The implied path follows the same moat-scored convergence toward the 2% terminal growth rate that the forward model uses.
The interactive version lets you change what is held fixed — margins, convergence timing, industry benchmarks — and overlays the market-implied growth path on your own editable forecast, so you can see exactly where your expectations and the market's diverge.
The implied growth re-solves when UroGen Pharma Ltd files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last solved 2026-07-17.